V. D. Dodge, E. M. Cox
Dodge & Cox Stock Fund
Dodge & Cox Stock Fund Sanofi ADR stake
total: 130
Dodge & Cox Stock Fund SNY trades
- Total transactions:
- 21
- New positions:
- 1
- Added:
- 5
- Reduced:
- 15
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Dodge & Cox Stock Fund holds 21,432,924 Sanofi ADR (SNY) shares with a market value of roughly $1.03B accounting for 0.90% of the overall portfolio. To date, the estimated cost basis is nearly $47.7 for "buy" trades and estimated average "sell" price is $48.41. Dodge & Cox Stock Fund first purchased SNY in 2019 Q3, initially acquiring about 40.34M shares. Since the initial investment in Sanofi ADR (SNY), Dodge & Cox Stock Fund has made 20 more transactions.
When did Dodge & Cox Stock Fund buy Sanofi ADR (SNY)?
Dodge & Cox Stock Fund first invested in Sanofi ADR (SNY) in 2019 Q3 at the reported quarter-end price of $46.33 per share.
What's the cost basis of Dodge & Cox Stock Fund's SNY stake?
The estimated cost basis for Sanofi ADR (SNY) stake is around $47.70 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $47.70
- Weighted AVG sell price:
- $48.41
Dodge & Cox Stock Fund's historical trades in Sanofi ADR
21 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.90%
|
21,432,924
|
$48.18
|
$1,032,638,278
|
-49.87% (-21,322,501)
|
-0.86%
|
|
2025 Q4
|
1.73%
|
42,755,425
|
$48.46
|
$2,071,927,896
|
-19.49% (-10,351,999)
|
-0.42%
|
|
2025 Q3
|
2.09%
|
53,107,424
|
$47.20
|
$2,506,670,413
|
-3.67% (-2,025,600)
|
-0.08%
|
|
2025 Q2
|
2.27%
|
55,133,024
|
$48.31
|
$2,663,476,389
|
-1.59% (-891,500)
|
-0.04%
|
|
2025 Q1
|
2.73%
|
56,024,524
|
$55.46
|
$3,107,120,101
|
-2.32% (-1,333,000)
|
-0.07%
|
|
2024 Q4
|
2.48%
|
57,357,524
|
$48.23
|
$2,766,353,383
|
-1.47% (-854,900)
|
-0.04%
|
|
2023 Q3
|
3.38%
|
58,212,424
|
$53.64
|
$3,122,514,423
|
-0.16% (-94,400)
|
-0.01%
|
|
2023 Q2
|
3.39%
|
58,306,824
|
$53.90
|
$3,142,737,814
|
-1.28% (-753,504)
|
-0.05%
|
|
2023 Q1
|
3.61%
|
59,060,328
|
$54.42
|
$3,214,063,050
|
-1.36% (-815,700)
|
-0.05%
|
|
2022 Q4
|
3.29%
|
59,876,028
|
$48.43
|
$2,899,796,036
|
+12.09% (+6,458,300)
|
+0.35%
|
|
2022 Q3
|
2.57%
|
$38.02
|
-1.05% (-567,800)
|
|||
|
2022 Q2
|
3.16%
|
$50.03
|
-16.97% (-11,033,600)
|
|||
|
2021 Q4
|
3.36%
|
$50.10
|
-0.53% (-346,700)
|
|||
|
2021 Q3
|
3.46%
|
$48.21
|
+39.67% (+18,565,150)
|
|||
|
2021 Q2
|
2.76%
|
$52.66
|
+2.04% (+937,850)
|
|||
|
2021 Q1
|
2.80%
|
$49.46
|
+81.49% (+20,592,007)
|
|||
|
2020 Q4
|
1.74%
|
$48.59
|
+2.42% (+597,993)
|
|||
|
2020 Q2
|
2.10%
|
$51.05
|
-19.51% (-5,978,900)
|
|||
|
2020 Q1
|
2.60%
|
$43.72
|
-22.47% (-8,885,100)
|
|||
|
2019 Q4
|
2.66%
|
$50.20
|
-1.98% (-800,500)
|
|||
|
2019 Q3
|
2.70%
|
$46.33
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.